Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.46 |
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.44 |
| ▸ | APLNR | P35414 | 1/20 | 0.44 |
| ▸ | SQOR | Q9Y6N5 | 1/20 | 0.43 |
| ▸ | P2RY1 | P47900 | 12/20 | 0.40 |
| ▸ | BTK | Q06187 | 1/20 | 0.40 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.38 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11972428 | 0.84 | APLNR (0.46) | SLC22A12NFE2L2APLNRSQORP2RY1 | |
| SCHEMBL30440802 | 0.82 | SLC22A12 (0.55) | SLC22A12NFE2L2APLNR | |
| SCHEMBL322870 | 0.82 | SLC22A12 (0.55) | SLC22A12NFE2L2APLNR | |
| SCHEMBL18869514 | 0.81 | SLC22A12 (0.42) | SLC22A12NFE2L2APLNRSQORP2RY1 | |
| SCHEMBL21970992 | 0.81 | SLC22A12 (0.42) | SLC22A12NFE2L2APLNRSQORP2RY1 | |
| SCHEMBL25407823 | 0.80 | SLC22A12 (0.47) | SLC22A12NFE2L2APLNRBTK | |
| SCHEMBL12922790 | 0.80 | MEN1 (0.42) | P2RY1 | |
| SCHEMBL25024226 | 0.80 | NFE2L2 (0.46) | SLC22A12NFE2L2APLNRP2RY1BTK | |
| SCHEMBL25023921 | 0.80 | PLCG1 (0.43) | SLC22A12NFE2L2APLNRSQORP2RY1 | |
| SCHEMBL30581481 | 0.80 | SLC22A12 (0.44) | SLC22A12NFE2L2APLNRSQORBTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 167 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238296-A1 | METHODS OF REGULATING BCL11A EXPRESSION AND TREATMENT OF BCL11A-MEDIATED DISORDERS | FULCRUM THERAPEUTICS INC (US) | 2024-07-18 | — | — | US | disclosed |
| US-20240238296-A1 | METHODS OF REGULATING BCL11A EXPRESSION AND TREATMENT OF BCL11A-MEDIATED DISORDERS | FULCRUM THERAPEUTICS INC (US) | 2024-07-18 | — | — | US | disclosed |
| US-11858957-B2 | Ectonucleotidase inhibitors and methods of use thereof | ANTENGENT THERAPEUTICS LIMITED (CN) | 2024-01-02 | — | — | US | disclosed |
| US-11858957-B2 | Ectonucleotidase inhibitors and methods of use thereof | ANTENGENT THERAPEUTICS LIMITED (CN) | 2024-01-02 | — | — | US | disclosed |
| US-20230399320-A1 | NOVEL CAPSID ASSEMBLY INHIBITOR | Pelemed Co., Ltd. (UA) | 2023-12-14 | — | — | US | disclosed |
| US-20230399320-A1 | NOVEL CAPSID ASSEMBLY INHIBITOR | Pelemed Co., Ltd. (UA) | 2023-12-14 | — | — | US | disclosed |
| EP-3956320-B1 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | JANSSEN BIOTECH INC (US) | 2023-11-29 | — | — | EP | disclosed |
| US-20230357165-A1 | QUINAZOLINONES DERIVATIVES FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE, PREPARATION AND USE THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2023-11-09 | — | — | US | disclosed |
| US-11771738-B2 | Endoparasitic depsipeptides | ZOETIS SERVICES LLC (US) | 2023-10-03 | — | — | US | disclosed |
| US-20230303570-A1 | KINASE INHIBITORS AND USES THEREOF | ABM THERAPEUTICS CORP (US) | 2023-09-28 | — | — | US | disclosed |
| US-7420066-B2 | Benzofuran derivatives useful for treating hyper-proliferative disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-09-02 | — | — | US | disclosed |
| US-20080132503-A1 | Inhibitors of Histone Deacetylase | METHYLGENE INC. (CA) | 2008-06-05 | — | — | US | disclosed |
| US-20080096874-A1 | Oxadiazole Derivative as Dgat Inhibitors | ASTRAZENECA AB (SE) | 2008-04-24 | — | — | US | disclosed |
| US-20080071095-A1 | Cystic fibrosis transmembrane conductance | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-03-20 | — | — | US | disclosed |
| US-20080004282-A1 | Compositions and methods for modulating gated ion channels | PAINCEPTOR PHARMA CORPORATION (CA) | 2008-01-03 | — | — | US | disclosed |
| US-20070287705-A1 | Crf Receptor Antagonists and Methods Relating Thereto | NEUROCRINE BIOSCIENCES, INC. | 2007-12-13 | — | — | US | disclosed |
| US-20070264196-A1 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED | 2007-11-15 | — | — | US | disclosed |
| US-20070225365-A1 | Cetp Inhibitors | MERCK & CO., INC. (US) | 2007-09-27 | — | — | US | disclosed |
| US-20070197628-A1 | Cannabinoid receptor modulators | INTERVET INTERNATIONAL B.V. (NL) | 2007-08-23 | — | — | US | disclosed |
| US-20070027321-A1 | Bipyridyl amines and ethers as modulators of metabotropic glutamate receptor-5 | MERCK SHARP & DOHME CORP. | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303570-A1 | KINASE INHIBITORS AND USES THEREOF | ERBB2, ERBB3, ERBB4 | SLC22A12 4388/4885NFE2L2 3308/4885APLNR 1909/4885 |
| US-20230357165-A1 | QUINAZOLINONES DERIVATIVES FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE, PREPARATION AND USE THEREOF | ATG7, GOT1, LIPC | SLC22A12 4376/4885NFE2L2 996/4885APLNR 3613/4885 |
| US-20070225365-A1 | Cetp Inhibitors | CETP, APOB, NPC1 | SLC22A12 1871/4885NFE2L2 1496/4885APLNR 4243/4885 |
| US-11858957-B2 | Ectonucleotidase inhibitors and methods of use thereof | NT5E, ENTPD5, NT5C2 | SLC22A12 2097/4885NFE2L2 2301/4885APLNR 859/4885 |
| US-20070287705-A1 | Crf Receptor Antagonists and Methods Relating Thereto | CRHR1, CRHR2, CRH | SLC22A12 991/4885NFE2L2 3071/4885APLNR 639/4885 |
| US-20240238296-A1 | METHODS OF REGULATING BCL11A EXPRESSION AND TREATMENT OF BCL11A-MEDIATED DISORDERS | BCLAF1, EED, BCL3 | SLC22A12 2005/4885NFE2L2 365/4885APLNR 2852/4885 |
| US-20070264196-A1 | Modulators of ATP-binding cassette transporters | CFTR, ABCB1, ABCC2 | SLC22A12 99/4885NFE2L2 1010/4885APLNR 1740/4885 |
| US-20080004282-A1 | Compositions and methods for modulating gated ion channels | KCNN3, KCNN2, HCN3 | SLC22A12 2765/4885NFE2L2 3988/4885APLNR 870/4885 |
| US-20070197628-A1 | Cannabinoid receptor modulators | CNR1, CNR2, GPR18 | SLC22A12 1868/4885NFE2L2 3604/4885APLNR 886/4885 |
| US-20070027321-A1 | Bipyridyl amines and ethers as modulators of metabotropic glutamate receptor-5 | GRM5, GRIK5, GRM1 | SLC22A12 3593/4885NFE2L2 1141/4885APLNR 356/4885 |
| US-11771738-B2 | Endoparasitic depsipeptides | VIP, PREP, VIPR1 | SLC22A12 890/4885NFE2L2 2376/4885APLNR 778/4885 |
| US-20080096874-A1 | Oxadiazole Derivative as Dgat Inhibitors | DGAT1, DGAT2, GPR119 | SLC22A12 693/4885NFE2L2 2936/4885APLNR 2930/4885 |
| US-20080071095-A1 | Cystic fibrosis transmembrane conductance | CFTR, ABCB1, ABCC1 | SLC22A12 98/4885NFE2L2 1208/4885APLNR 1000/4885 |
| US-20080132503-A1 | Inhibitors of Histone Deacetylase | HDAC1, HDAC5, HDAC3 | SLC22A12 4055/4885NFE2L2 1963/4885APLNR 2406/4885 |
| US-20230399320-A1 | NOVEL CAPSID ASSEMBLY INHIBITOR | ZC3HAV1, COPB1, CNBP | SLC22A12 4458/4885NFE2L2 4170/4885APLNR 3552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.